At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
Leflunomide +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Dose-Escalation Trial of Leflunomide in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis, Leflunomide, and 1 other intervention for Recurrent Plasma Cell Myeloma and Refractory Plasma Cell Myeloma. Completed, enrolled 12 participants across 1 site.
Detailed Summary
This phase I/II trial studies the side effects and best dose of leflunomide in treating patients with multiple myeloma that has come back (relapsed) or has not responded to previous treatment (refractory). Leflunomide may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 2015
Enrollment StartDec 2015
Primary CompletionSep 2018
Study CompletionJun 2022
TodayJul 2026
First PostedJul 27, 2015
Enrollment StartDec 2, 2015
Primary CompletionSep 18, 2018
Study CompletionJun 9, 2022
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 10.9 years ago
Interventions
Laboratory Biomarker Analysisother
Correlative studies
Leflunomidedrug
Given PO
Pharmacological Studyother
Correlative studies